^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Nasopharyngeal Carcinoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
12/08/2021
Excerpt:
SYSTEMIC THERAPY FOR NASOPHARYNGEAL CANCERS: Other Recommended Regimens...Cisplatin/gemcitabine + PD-1 inhibitor (eg pembrolizumab or nivolumab)
Secondary therapy:
cisplatin + gemcitabine
